Jazz Pharmaceuticals plc

Pharmaceutical Preparations·DUBLIN·FY end 12/31·CIK 1232524

CEO Pay Ratio

55:1

Bruce C. Cozadd

CEO Total Comp

$15.5M

Bruce C. Cozadd

Median Employee

$281,421

Revenue

$4.3B

FY 2025

Net Income

-$356.1M

FY 2025

Free Cash Flow

$1.3B

FY 2025

Net Margin

-8.3%

Insider Net (180d)

-$16.5M

0 buys / 23 sales

CEO Pay Accountability

CEO comp as % of net income

2.77%

For every $1,000 of profit, $27.72 flows to the CEO.

CEO comp as % of buybacks

4.99%

CEO comp equals 49.9‰ of cash returned to shareholders via buybacks.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$4.3B	$4.1B	$3.8B	$3.7B	$3.1B
Gross Profit	—	—	—	—	—	—
Operating Income	-$430.2M	$716.6M	$578.6M	-$65.5M	$170.3M
Net Income	-$356.1M	$560.1M	$414.8M	-$224.1M	-$329.7M
Operating CF	$1.4B	$1.4B	$1.1B	$1.3B	$778.5M
Capex	$58.8M	$38.1M	$24.0M	$29.0M	$27.6M
Free Cash Flow	$1.3B	$1.4B	$1.1B	$1.2B	$750.9M
Buybacks	$125.0M	$311.4M	$269.8M	$54.0K	$0
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	-10.1%	17.6%	15.1%	-1.8%	5.5%
Net Margin	-8.3%	13.8%	10.8%	-6.1%	-10.7%
FCF Margin	30.4%	33.4%	27.9%	34.0%	24.3%
R&D / Revenue	—	—	—	—	—	—
Effective Tax	—	—	—	—	—	—
Debt / Equity	2.24	2.98	2.90	3.70	3.04
Buybacks / FCF	9.6%	22.9%	25.3%	0.0%	0.0%

FY 2024

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Bruce C. CozaddChairperson and CEO	$1.2M	$12.8M	—	$1.5M	$31.8K	$15.5M
Renée GaláPresident and COO	$824.9K	$5.1M	—	$697.0K	$27.6K	$6.6M
Robert IannoneM.D., M.S.C.E Executive Vice President, Global Head of R&D	$750.7K	$4.3M	—	$598.0K	$23.4K	$5.7M